Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors
GlobeNewswire - Mon May 05, 6:00AM CDT
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Mark Leuchtenberger as Non-Executive Chairman of the Board of Directors.
Xenetic Biosciences Announces Full Year 2013 Financial Results and Business Update
GlobeNewswire - Wed Apr 16, 6:01AM CDT
Xenetic BioSciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel orphan oncology therapeutics, today reported financial results for the year-ended December 31, 2013.
Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis
GlobeNewswire - Mon Apr 07, 6:06AM CDT
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the positive results from its Phase I clinical trial of PulmoXen for the treatment of cystic fibrosis. The single center, open-label trial was conducted in Russia by Xenetic's partner, OJSC Pharmsynthez. In this First-in-Human study, PulmoXen was administered to 12 healthy volunteers via inhalation daily for seven days, in two doses of 2500IU and 5000IU, and was found to be safe and well tolerated. PulmoXen is a novel, modified form of recombinant human DNase I (rhDNase I) designed to be a next-generation version of Pulmozyme.
Xenetic Biosciences Appoints Darlene Deptula-Hicks to Board of Directors
GlobeNewswire - Fri Apr 04, 7:17AM CDT
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Darlene Deptula-Hicks to its Board of Directors.
Xenetic Biosciences Announces Opening of Corporate Headquarters and R&D Facility in Lexington, MA
GlobeNewswire - Tue Mar 04, 7:14AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the opening of its new corporate headquarters and research and development facility in Lexington, MA. Xenetic, in collaboration with the Massachusetts Life Sciences Center (MLSC) and the Massachusetts Biotechnology Council (MassBio), will host a grand opening and ribbon cutting ceremony today to celebrate the completion of the Company's relocation of its global headquarters to Lexington from London, UK.
Xenetic Biosciences Announces Ticker Symbol Change to XBIO
GlobeNewswire - Fri Feb 14, 6:01AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced that its common stock has commenced trading under new ticker symbol "XBIO" on the OTC Bulletin Board (OTCBB). Since changing its name in January, the Company has traded on the OTCBB under the ticker symbol "GAIFD."